Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term inclacumab extension study in sickle cell disease
PACTR202108532761448Phase 3Unknown
- Sponsor
- Pfizer
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of inclacumab in sickle cell disease (SCD), sponsored by Pfizer. Primary endpoint: Long-term safety of inclacumab. Status: unknown.
02
Drugs
inclacumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202108532761448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202108532761448.